ADTX
Aditxt, Inc.
Price Chart
Latest Quote
$0.80
Current Price| Previous Close | $0.82 |
| Open | $0.79 |
| Day High | $0.81 |
| Day Low | $0.71 |
| Volume | 217,550 |
Stock Information
| Shares Outstanding | 1.78M |
| Total Debt | $5.67M |
| Cash Equivalents | $163K |
| Revenue | $6K |
| Net Income | $-42.24M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.42M |
| EPS (TTM) | $-829.58 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 7/42| Debt to Equity | 0.78 |
| Debt to Earnings | -14.02 |
| Current Ratio | 0.09 |
| Quick Ratio | 0.08 |
| Avg Revenue Growth | 6.89% |
| Profit Margin | -25709.21% |
| Return on Equity | -388.37% |
| Avg FCF Growth | -7.01% |
| FCF Yield | -1183.75% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.80 | 217,702 |
| 2026-01-30 | $0.82 | 139,700 |
| 2026-01-29 | $0.82 | 451,300 |
| 2026-01-28 | $0.92 | 213,800 |
| 2026-01-27 | $0.97 | 257,400 |
| 2026-01-26 | $0.91 | 767,000 |
| 2026-01-23 | $1.17 | 1,205,500 |
| 2026-01-22 | $1.17 | 2,296,600 |
| 2026-01-21 | $1.46 | 25,425,800 |
| 2026-01-20 | $1.18 | 39,269,100 |
| 2026-01-16 | $0.87 | 4,088,500 |
| 2026-01-15 | $0.74 | 162,500 |
| 2026-01-14 | $0.73 | 206,600 |
| 2026-01-13 | $0.75 | 268,600 |
| 2026-01-12 | $0.81 | 215,900 |
| 2026-01-09 | $0.79 | 298,300 |
| 2026-01-08 | $0.84 | 183,200 |
| 2026-01-07 | $0.84 | 222,700 |
| 2026-01-06 | $0.88 | 252,200 |
| 2026-01-05 | $0.95 | 290,200 |
About Aditxt, Inc.
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
đ° Latest News
Wall Street Set to Open Higher Wednesday as Investors Dissect Mixed Jobs Report, Look Ahead to Thursday's Inflation Data
MT Newswires âĸ 2025-12-17T13:53:43ZBC-Most Active Stocks
Associated Press Finance âĸ 2025-10-28T14:30:18ZWhy Aditxt Inc. (ADTX) Went Down On Thursday?
Insider Monkey âĸ 2025-04-10T13:24:27Z
Aditxt subsidiary Persanta engages Dominary Securities for IPO
TipRanks âĸ 2025-02-22T13:45:48Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $627,474 | $756,836 | $766,779 | $77,979 |
| Cost Of Revenue | $627,474 | $756,836 | $766,779 | $77,979 |
| Total Revenue | $133,985 | $645,176 | $933,715 | $105,034 |
| Operating Revenue | $133,985 | $645,176 | $933,715 | $105,034 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $7,363,645 | $6,389,900 | $2,286,086 | $1,938,567 |
| Total Expenses | $27,997,683 | $26,707,601 | $25,869,875 | $27,539,962 |
| Other Income Expense | $205,831 | $51,712 | $-484,978 | $-17,000,970 |
| Other Non Operating Income Expenses | $-208,670 | $51,712 | $58,960 | - |
| Net Non Operating Interest Income Expense | $-7,362,191 | $-6,379,734 | $-2,228,738 | $-1,935,466 |
| Interest Expense Non Operating | $7,363,645 | $6,389,900 | $2,286,086 | $1,938,567 |
| Operating Expense | $27,370,209 | $25,950,765 | $25,103,096 | $27,461,983 |
| Selling And Marketing Expense | $197,863 | $269,284 | $1,849,460 | $334,977 |
| General And Administrative Expense | $16,286,216 | $18,607,142 | $15,985,552 | $22,084,389 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-34,446,486 | $-32,380,839 | $-27,649,876 | $-46,371,364 |
| Net Interest Income | $-7,362,191 | $-6,379,734 | $-2,228,738 | $-1,935,466 |
| Interest Income | $1,454 | $10,166 | $57,348 | $3,101 |
| Normalized Income | $-34,860,987 | $-32,380,839 | $-27,105,938 | $-29,370,394 |
| Net Income From Continuing And Discontinued Operation | $-34,446,486 | $-32,380,839 | $-27,649,876 | $-46,371,364 |
| Total Operating Income As Reported | $-27,863,698 | $-26,062,425 | $-25,480,098 | $-41,934,928 |
| Net Income Common Stockholders | $-40,353,497 | $-32,700,710 | $-27,687,553 | $-46,371,364 |
| Net Income | $-34,446,486 | $-32,380,839 | $-27,649,876 | $-46,371,364 |
| Net Income Including Noncontrolling Interests | $-35,020,058 | $-32,390,447 | $-27,649,876 | $-46,371,364 |
| Net Income Continuous Operations | $-35,020,058 | $-32,390,447 | $-27,649,876 | $-46,371,364 |
| Pretax Income | $-35,020,058 | $-32,390,447 | $-27,649,876 | $-46,371,364 |
| Interest Income Non Operating | $1,454 | $10,166 | $57,348 | $3,101 |
| Operating Income | $-27,863,698 | $-26,062,425 | $-24,936,160 | $-27,434,928 |
| Gross Profit | $-493,489 | $-111,660 | $166,936 | $27,055 |
| Special Income Charges | - | $0 | $-543,938 | $-17,000,970 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-311.18 | $-249623.74 | $-2768755.30 | $-23185682.00 |
| Basic EPS | $-311.18 | $-249623.74 | $-2768755.30 | $-23185682.00 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,453,663 | $-25,457,964 | $-24,283,875 | $-26,955,591 |
| Total Unusual Items | $414,501 | $0 | $-543,938 | $-17,000,970 |
| Total Unusual Items Excluding Goodwill | $414,501 | $0 | $-543,938 | $-17,000,970 |
| Reconciled Depreciation | $617,251 | $542,583 | $535,977 | $476,236 |
| EBITDA (Bullshit earnings) | $-27,039,162 | $-25,457,964 | $-24,827,813 | $-43,956,561 |
| EBIT | $-27,656,413 | $-26,000,547 | $-25,363,790 | $-44,432,797 |
| Diluted Average Shares | $129,679 | $131 | $10 | $2 |
| Basic Average Shares | $129,679 | $131 | $10 | $2 |
| Diluted NI Availto Com Stockholders | $-40,353,497 | $-32,700,710 | $-27,687,553 | $-46,371,364 |
| Otherunder Preferred Stock Dividend | $5,907,011 | $319,871 | $37,667 | - |
| Minority Interests | $573,572 | $9,608 | $0 | - |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $414,501 | $51,712 | - | - |
| Research And Development | $10,886,130 | $7,074,339 | $7,268,084 | $5,042,617 |
| Selling General And Administration | $16,484,079 | $18,876,426 | $17,835,012 | $22,419,366 |
| Other Gand A | $16,286,216 | $18,607,142 | $15,985,552 | $22,084,389 |
| Write Off | - | $0 | $543,938 | $14,500,000 |
| Other Special Charges | - | - | - | $2,500,970 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $8,863,465 | $16,046,933 | $5,099,307 | $9,966,773 |
| Total Assets | $32,144,390 | $44,578,327 | $10,735,249 | $16,663,907 |
| Total Non Current Assets | $30,144,549 | $37,665,379 | $5,991,686 | $7,247,203 |
| Non Current Prepaid Assets | $87,672 | $11,280,182 | $355,366 | $379,250 |
| Goodwill And Other Intangible Assets | $6,111 | $9,444 | $107,000 | $214,000 |
| Other Intangible Assets | $6,111 | $9,444 | $107,000 | $214,000 |
| Current Assets | $1,999,841 | $6,912,948 | $4,743,563 | $9,416,704 |
| Prepaid Assets | $3,379 | $217,390 | $496,869 | $460,102 |
| Inventory | $11,245 | $745,502 | $950,093 | $494,697 |
| Receivables | $1,152,186 | $5,852,954 | $527,961 | $589,844 |
| Other Receivables | $1,108,751 | $5,444,628 | - | - |
| Accounts Receivable | $43,435 | $408,326 | $527,961 | $89,844 |
| Allowance For Doubtful Accounts Receivable | $-4,000 | $0 | $-18,634 | - |
| Gross Accounts Receivable | $47,435 | $408,326 | $546,595 | - |
| Cash Cash Equivalents And Short Term Investments | $833,031 | $97,102 | $2,768,640 | $7,872,061 |
| Cash And Cash Equivalents | $833,031 | $97,102 | $2,768,640 | $7,872,061 |
| Cash Financial | $833,031 | $97,102 | $2,768,640 | $7,872,061 |
| Non Current Deferred Assets | - | $0 | $50,000 | $0 |
| Notes Receivable | - | - | $0 | $500,000 |
| Other Non Current Assets | - | - | - | $289,539 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $4,967,652 | $16,079,198 | - | - |
| Total Debt | $6,920,389 | $18,217,987 | $3,381,859 | $4,721,533 |
| Long Term Debt And Capital Lease Obligation | $436,354 | $1,041,744 | $1,885,218 | $2,875,974 |
| Current Debt And Capital Lease Obligation | $6,484,035 | $17,176,243 | $1,496,641 | $1,845,559 |
| Current Debt | $5,800,683 | $16,176,300 | $409,983 | $700,433 |
| Other Current Borrowings | $147,823 | $147,823 | $409,983 | $700,433 |
| Long Term Debt | - | - | - | $110,041 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $23,857,994 | $28,531,558 | $5,528,942 | $6,483,134 |
| Total Non Current Liabilities Net Minority Interest | $450,871 | $2,641,744 | $1,885,218 | $2,875,974 |
| Derivative Product Liabilities | $14,517 | $0 | - | - |
| Current Liabilities | $23,407,123 | $25,889,814 | $3,643,724 | $3,607,160 |
| Other Current Liabilities | $1,354,774 | - | - | - |
| Current Deferred Liabilities | $106,075 | $158,612 | $188,581 | $186,058 |
| Current Notes Payable | $5,652,860 | $16,028,477 | $0 | - |
| Payables And Accrued Expenses | $15,462,239 | $8,554,959 | $1,958,502 | $1,575,543 |
| Interest Payable | $1,889,527 | $387,692 | - | - |
| Payables | $12,442,373 | $7,523,658 | - | - |
| Other Payable | $2,250,000 | - | - | - |
| Accounts Payable | $10,192,373 | $7,523,658 | - | - |
| Other Non Current Liabilities | - | $1,600,000 | - | - |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $496,548 | $16,056,352 | $5,206,307 | $10,180,773 |
| Preferred Stock Equity | $8,373,028 | $25 | - | - |
| Total Equity Gross Minority Interest | $8,286,396 | $16,046,769 | $5,206,307 | $10,180,773 |
| Stockholders Equity | $8,869,576 | $16,056,377 | $5,206,307 | $10,180,773 |
| Retained Earnings | $-168,094,569 | $-127,741,072 | $-95,040,362 | $-67,352,809 |
| Long Term Equity Investment | $27,277,211 | $22,277,211 | $0 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $1 | $0 | $0 | $0 |
| Ordinary Shares Number | $129,679 | $131 | $10 | $2 |
| Share Issued | $129,680 | $131 | $10 | $2 |
| Tangible Book Value | $490,437 | $16,046,908 | $5,099,307 | $9,966,773 |
| Invested Capital | $6,297,231 | $32,232,652 | $5,616,290 | $10,991,247 |
| Working Capital | $-21,407,282 | $-18,976,866 | $1,099,839 | $5,809,544 |
| Capital Lease Obligations | $1,119,706 | $2,041,687 | $2,971,876 | $3,911,059 |
| Total Capitalization | $8,869,576 | $16,056,377 | $5,206,307 | $10,290,814 |
| Minority Interest | $-583,180 | $-9,608 | $0 | - |
| Treasury Stock | $201,605 | $201,605 | $201,605 | $201,605 |
| Additional Paid In Capital | $168,792,592 | $143,999,018 | $100,448,166 | $77,734,288 |
| Capital Stock | $8,373,158 | $36 | $108 | $899 |
| Common Stock | $130 | $11 | $108 | $899 |
| Preferred Stock | $8,373,028 | $25 | $0 | $0 |
| Long Term Capital Lease Obligation | $436,354 | $1,041,744 | $1,885,218 | $2,765,933 |
| Current Capital Lease Obligation | $683,352 | $999,943 | $1,086,658 | $1,145,126 |
| Current Accrued Expenses | $3,019,866 | $1,031,301 | - | - |
| Investments And Advances | $27,277,211 | $22,277,211 | $0 | - |
| Investmentsin Subsidiariesat Cost | $27,277,211 | $22,277,211 | $0 | - |
| Net PPE | $2,773,555 | $4,098,542 | $5,479,320 | $6,364,414 |
| Accumulated Depreciation | $-1,842,728 | $-1,251,015 | $-815,987 | $-387,010 |
| Gross PPE | $4,616,283 | $5,349,557 | $6,295,307 | $6,751,424 |
| Leases | $120,440 | $120,440 | $120,440 | - |
| Other Properties | $4,060,707 | $4,793,981 | $2,581,325 | $6,348,178 |
| Machinery Furniture Equipment | $435,136 | $435,136 | $433,085 | $403,246 |
| Properties | $0 | $0 | $0 | - |
| Buildings And Improvements | - | $2,200,299 | $3,160,457 | - |
| Raw Materials | - | - | $950,093 | $494,697 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-16,762,121 | $-19,218,074 | $-22,759,085 | $-23,293,896 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-16,762,121 | $-19,203,667 | $-22,392,006 | $-22,278,144 |
| Cash Flow From Continuing Operating Activities | $-16,762,121 | $-19,203,667 | $-22,392,006 | $-22,278,144 |
| Operating Gains Losses | $-411,501 | - | $6,976 | $2,500,970 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Investing Cash Flow | $-5,000,000 | $-14,407 | $-241,918 | $-16,305,291 |
| Cash Flow From Continuing Investing Activities | $-5,000,000 | $-14,407 | $-241,918 | $-16,305,291 |
| Capital Expenditure | - | $-14,407 | $-367,079 | $-1,015,752 |
| Net Other Investing Changes | - | - | $125,161 | $-15,289,539 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-2,851,871 | $-1,000 | $-20,000 | $0 |
| Issuance Of Capital Stock | $21,166,343 | $11,055,883 | $17,253,307 | $29,868,611 |
| Financing Cash Flow | $22,498,050 | $16,546,536 | $17,530,503 | $35,954,670 |
| Cash Flow From Continuing Financing Activities | $22,498,050 | $16,546,536 | $17,530,503 | $35,954,670 |
| Net Other Financing Charges | $4,335,877 | $-261,160 | $-400,491 | $-1,200,000 |
| Net Preferred Stock Issuance | $-2,851,871 | $0 | $0 | $0 |
| Preferred Stock Issuance | $0 | $1,000 | $20,000 | $0 |
| Net Common Stock Issuance | $21,166,343 | $11,054,883 | $17,233,307 | $29,868,611 |
| Common Stock Issuance | $21,166,343 | $11,054,883 | $17,233,307 | $29,868,611 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-6,014,942 | $-3,840,011 | $-3,286,887 | $-914,766 |
| Issuance Of Debt | $4,616,153 | $9,592,824 | $2,875,000 | $4,473,540 |
| Interest Paid Supplemental Data | $1,235,640 | $3,070,620 | $753,038 | $15,789 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $833,031 | $97,102 | $2,768,640 | $7,872,061 |
| Beginning Cash Position | $97,102 | $2,768,640 | $7,872,061 | $10,500,826 |
| Changes In Cash | $735,929 | $-2,671,538 | $-5,103,421 | $-2,628,765 |
| Proceeds From Stock Option Exercised | $1,246,490 | $0 | $1,109,574 | $3,727,285 |
| Preferred Stock Payments | $-2,851,871 | $-1,000 | $-20,000 | $0 |
| Net Issuance Payments Of Debt | $-1,398,789 | $5,752,813 | $-411,887 | $3,558,774 |
| Net Short Term Debt Issuance | $-1,398,789 | $5,752,813 | $-411,887 | $-315,790 |
| Short Term Debt Payments | $-6,014,942 | $-3,840,011 | $-3,286,887 | $-315,790 |
| Short Term Debt Issuance | $4,616,153 | $9,592,824 | $2,875,000 | - |
| Net Investment Purchase And Sale | $-5,000,000 | $0 | - | - |
| Purchase Of Investment | $-5,000,000 | $0 | - | - |
| Net PPE Purchase And Sale | $0 | $-14,407 | $-367,079 | $-1,015,752 |
| Purchase Of PPE | $0 | $-14,407 | $-367,079 | $-1,015,752 |
| Change In Working Capital | $7,093,988 | $9,099,118 | $-493,437 | $129,975 |
| Change In Other Current Liabilities | $667,000 | $1,600,000 | $0 | - |
| Change In Payables And Accrued Expense | $5,095,091 | $6,646,457 | $412,959 | $1,333,930 |
| Change In Prepaid Assets | $232,749 | $528,435 | $-12,883 | $-396,798 |
| Change In Inventory | $734,257 | $204,591 | $-455,396 | $-494,697 |
| Change In Receivables | $364,891 | $119,635 | $-438,117 | $-312,460 |
| Changes In Account Receivables | $364,891 | $119,635 | $-438,117 | $-312,460 |
| Other Non Cash Items | $4,212,465 | $2,143,061 | $1,533,048 | $1,845,358 |
| Stock Based Compensation | $6,745,734 | $1,402,018 | $3,131,368 | $4,640,681 |
| Depreciation Amortization Depletion | $617,251 | $542,583 | $535,977 | $476,236 |
| Depreciation And Amortization | $617,251 | $542,583 | $535,977 | $476,236 |
| Amortization Cash Flow | $3,333 | $107,556 | $107,000 | $107,000 |
| Amortization Of Intangibles | $3,333 | $107,556 | $107,000 | $107,000 |
| Depreciation | $613,918 | $435,027 | $428,977 | $369,236 |
| Gain Loss On Investment Securities | $-414,501 | - | - | - |
| Gain Loss On Sale Of PPE | $3,000 | $0 | $6,976 | $0 |
| Net Income From Continuing Operations | $-35,020,058 | $-32,390,447 | $-27,649,876 | $-46,371,364 |
| Asset Impairment Charge | - | $0 | $543,938 | $14,500,000 |
| Net Long Term Debt Issuance | - | - | $-812,378 | $3,558,774 |
| Long Term Debt Payments | - | - | $-3,687,378 | $-914,766 |
| Long Term Debt Issuance | - | - | $2,875,000 | $4,473,540 |